A new study by Novo Nordisk shows that a 7.2 milligram dose of semaglutide leads to significant weight loss in individuals with obesity, exceeding the effects of currently available semaglutide-based medications.
Novo Nordisk's STEP UP trial, involving over 1,400 individuals with obesity, yielded remarkable results with a 7.2 milligram dose of semaglutide. Participants on this dose achieved an average weight loss of around 20% over a 72-week period, surpassing the typical outcomes observed with existing semaglutide-based medications like Ozempic and Wegovy. Semaglutide, the active ingredient in Ozempic and Wegovy, mimics the hormone GLP-1 , which plays a crucial role in regulating hunger and metabolism.
While Wegovy, approved by the FDA in 2021, is currently the highest-dose formulation of semaglutide available (up to 2.4 milligrams), Novo Nordisk aims to push the boundaries of its effectiveness. The STEP UP trial compared three groups: placebo, a 2.4 milligram dose (Wegovy's maximum), and a 7.2 milligram dose. Participants adhering fully to the weekly subcutaneous injections demonstrated a significant 20.7% body weight loss with the 7.2 milligram dose compared to 17.5% with the 2.4 milligram dose and 2.4% with the placebo. Even considering those with partial adherence, the higher dose still outperformed Wegovy at 18.7% compared to 15.6%. Importantly, the 7.2 milligram dose appeared to be generally safe and tolerable, with comparable side effects to the lower dose group, primarily gastrointestinal issues like diarrhea or vomiting.This groundbreaking study strengthens the clinical profile of semaglutide for obesity treatment, adding to the established health benefits of Wegovy. Novo Nordisk will soon release results from its STEP UP T2D trial, which evaluated a 7.2 milligram dose for individuals with obesity and type 2 diabetes. The company anticipates semaglutide to remain a leading treatment for both obesity and diabetes, despite competition from other drug candidates. However, even the highest-dose version faces stiff competition from drugs like Eli Lilly's tirzepatide, which has demonstrated superior weight loss results. Cost is another factor to consider, as the current lower-dose semaglutide formulations have high list prices, sparking concerns about affordability
OBESITY SEMAGLUTIDE NOVONORDISK WEIGHT LOSS CLINICAL TRIAL GLP-1 DIABETES TREATMENT
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
European markets higher in shortened session ahead of Christmas; Novo Nordisk resumes recoveryEuropean stocks edged higher on Tuesday, with all sectors trading in positive territory.
Read more »
Novo Nordisk shares plunge 24% after CagriSema obesity drug trial resultsShares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
Read more »
Novo Nordisk shares plunge 24% after disappointing trial results; Lilly jumps in premarketShares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
Read more »
Novo Nordisk shares plunge 17% after disappointing trial results; Lilly jumps in premarketShares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
Read more »
FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fallFedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall
Read more »
Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarketShares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
Read more »